GM1 gangliosidosis: patients with different phenotypic features and novel mutations.
Merve Emecen SanliMustafa DoganPublished in: Journal of pediatric endocrinology & metabolism : JPEM (2023)
In this study, we identified four patients with different phenotypic features and two new mutations. GM1 gangliosidosis shows clinical heterogeneity according to age of onset. In some patients, developmental delay can be seen before the loss of gained functions. Therefore, this disorder should be kept in mind in patients with developmental delay who have not yet started neurodegeneration. There is no curative treatment for the disease yet, but ongoing gene therapy studies are promising for curing the disease in the future.